Amanda J. Linke

Amanda J. Linke

Auto-generated profile, based on publicly available information

Amanda J. Linke

Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2024 in Cancer Research
Verified
Journal Article
Closed access
BDBrianna R. Daley
Brianna R. Daley
NSNancy E. Sealover
Nancy E. Sealover
BFBridget A. Finniff
Bridget A. Finniff
JHJacob M. Hughes
Jacob M. Hughes
ESErin Sheffels
Erin Sheffels
RKRobert Kortum
Robert Kortum
The clinical effectiveness of KRASG12C inhibitors (G12Ci) is limited both by intrinsic and acquired resistance, necessitating the development of combination approaches. Here, we identified targeting proximal receptor tyrosine kinase signaling using the SOS1 inhibitor (SOS1i) BI-3406 as a strategy to improve responses to G12Ci treatment. SOS1i enhanced the efficacy of G12Ci and limited rebound receptor tyrosine kinase/ERK signaling to overcome intrinsic/adaptive resistance, but this effect was modulated by SOS2 protein levels. G12Ci drug-tolerant persister (DTP) cells showed up to a 3-fold enrichment of tumor-initiating cells (TIC), suggestive of a sanctuary population of G12Ci-resistant cells. SOS1i resensitized DTPs to G12Ci and inhibited G12C-induced TIC enrichment. Co-mutation of the tumor suppressor KEAP1 limited the clinical effectiveness of G12Ci, and KEAP1 and STK11 deletion increased TIC frequency and accelerated the development of acquired resistance to G12Ci, consistent with clinical G12Ci resistance seen with these co-mutations. Treatment with SOS1i both delayed acquired G12Ci resistance and limited the total number of resistant colonies regardless of KEAP1 and STK11 mutational status. Together, these data suggest that targeting SOS1 could be an effective strategy to both enhance G12Ci efficacy and prevent G12Ci resistance regardless of co-mutations. Significance: The SOS1 inhibitor BI-3406 both inhibits intrinsic/adaptive resistance and targets drug tolerant persister cells to limit the development of acquired resistance to clinical KRASG12C inhibitors in lung adenocarcinoma cells.

24 October 2025 in Cancer Research
Verified
Journal Article
Open access
RBRachel Abigail Burge
Rachel Abigail Burge
LBLucas Bialousow
Lucas Bialousow
ALAmanda J. Linke
Amanda J. Linke
HCHannah S. Coalson
Hannah S. Coalson
SASara J Adair
Sara J Adair
GHGuy Aaron Hobbs
Guy Aaron Hobbs
Pancreatic ductal adenocarcinoma (PDAC) is defined by the near universal occurrence of KRAS mutations. The KRASG12R mutation is detected in approximately 15% to 20% of patients with PDAC and rare in other KRAS-mutant cancers. KRASG12R is unable to activate the lipid kinase PIK3CA, suggesting that alternative mechanisms might be employed to activate KRASG12R-independent PI3K signaling in PDAC. In this study, we detected elevated expression of all four PI3K isoforms in PDAC cell lines, with the PIK3CG isoform showing higher overall expression in KRASG12R-mutant PDAC. All four PI3K isoforms contributed to global PI3K signaling, and inhibition of any single isoform was insufficient to limit PDAC proliferation. The combined inhibition of all PI3K isoforms was required to limit proliferation, providing a potential explanation for the limited efficacy of PI3K inhibitors in the clinic. Additionally, PTEN, a negative regulator of PI3K signaling, was inactivated in PDAC by the formation of an intramolecular disulfide, which elevated overall PI3K signaling and reduced the dependency of PI3K signaling on KRAS. Oxidation of PTEN was independent of KRAS mutation status. Finally, nutrient-limiting conditions mimicking the PDAC tumor microenvironment further elevated PTEN oxidation and significantly increased macropinocytosis. Thus, this study uncovered a mechanism that supports elevated PI3K signaling in PDAC, thereby reducing the need for KRAS to directly activate the PI3K pathway. Significance: PTEN inactivation by intramolecular disulfide bond formation and elevated expression of PI3K isoforms in pancreatic cancer leads to unchecked KRAS-independent PI3K signaling, highlighting the need for therapeutic approaches targeting constitutive PI3K signaling. See related commentary by Tiriac and Engle, p. 1817 See related article by Burge et al., p. 1868 See related article by Kamgar et al., p. 2042

16 September 2025 in Science Signaling
Verified
Journal Article
Closed access
NSNancy E. Sealover
Nancy E. Sealover
BFBridget A. Finniff
Bridget A. Finniff
JHJacob M. Hughes
Jacob M. Hughes
ESErin Sheffels
Erin Sheffels
HLHyun Lee
Hyun Lee
RKRobert Kortum
Robert Kortum
Mutated RAS proteins activate downstream effector pathways (RAF-MEK-ERK and PI3K-AKT) to drive oncogenic transformation and progression. Because RAS family members differentially engage these pathways, combined inhibition of both pathways is required to effectively treat RAS -mutated cancers. Here, we found that this was due to signaling contributed by wild-type RAS family members that activated an effector pathway that was poorly engaged by the mutant RAS family member. Wild-type KRAS and NRAS promoted RAF-MEK-ERK signaling in cells expressing mutant HRAS, whereas wild-type HRAS and NRAS promoted PI3K-AKT signaling in cells expressing mutant KRAS. Combining inhibitors targeting the poorly engaged RAS effector pathways with inhibitors targeting the mutant RAS resulted in synergistic cytotoxicity in a manner that depended on wild-type RAS expression. The farnesyltransferase inhibitor tipifarnib blocked mutant HRAS-PI3K signaling and synergized with MEK inhibitors in HRAS -mutated cells, whereas KRAS G12C inhibitors blocked mutant KRAS-MEK signaling and synergized with PI3K inhibitors in KRAS G12C -mutated cells. Synergy was abolished in MEFs lacking all RAS proteins and in cancer cell lines in which nonmutated RAS family members were deleted. Our data highlight the critical role of wild-type RAS family members in supporting mutant RAS signaling and its importance as a therapeutic cotarget in RAS -mutated cancers.

17 June 2026
Verified
Other
Open access
RBRachel Abigail Burge
Rachel Abigail Burge
LBLucas Bialousow
Lucas Bialousow
ALAmanda J. Linke
Amanda J. Linke
HCHannah S. Coalson
Hannah S. Coalson
SASara J Adair
Sara J Adair
GHGuy Aaron Hobbs
Guy Aaron Hobbs
Ubiquitous expression of all four PI3K isoforms in PDAC

17 June 2026
Verified
Other
Open access
RBRachel Abigail Burge
Rachel Abigail Burge
LBLucas Bialousow
Lucas Bialousow
ALAmanda J. Linke
Amanda J. Linke
HCHannah S. Coalson
Hannah S. Coalson
SASara J Adair
Sara J Adair
GHGuy Aaron Hobbs
Guy Aaron Hobbs
Supplemental Table 1: Published Cellular IC50 values of PI3K inhibitors

17 June 2026
Verified
Other
Open access
PDF file
BDBrianna R. Daley
Brianna R. Daley
NSNancy E. Sealover
Nancy E. Sealover
BFBridget A. Finniff
Bridget A. Finniff
JHJacob M. Hughes
Jacob M. Hughes
ESErin Sheffels
Erin Sheffels
RKRobert Kortum
Robert Kortum
SOS1i synergizes with G12Ci to drive transcriptional changes regulating MAPK signaling.